Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dosimetry of 177Lu-PSMA-EB-01 in mCRPC
NCT05613738Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 177Lu-PSMA-EB-01 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Dosimetry of normal organs and tumors at 4 weeks, Hematologic adverse events collection at 6 months and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
177Lu-PSMA-EB-01
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05613738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613738.